Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomic...

Celý popis

Podrobná bibliografia

Vydané v:	Clinical cancer research Ročník 22; číslo 23; s. 5765 - 5771
Hlavní autori:	Kickingereder, Philipp, Götz, Michael, Muschelli, John, Wick, Antje, Neuberger, Ulf, Shinohara, Russell T, Sill, Martin, Nowosielski, Martha, Schlemmer, Heinz-Peter, Radbruch, Alexander, Wick, Wolfgang, Bendszus, Martin, Maier-Hein, Klaus H, Bonekamp, David
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2016
ISSN:	1078-0432, 1557-3265
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!